Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

MAD-CoV 2

Financiado

Cerrado

Modern approaches for developing antivirals against SARS CoV 2

The SARS-CoV-2 pandemic has become an unprecedented burden to public health, our civil societies and the global economy. To provide frontline therapies for COVID-19 and future corona virus outbreaks requires a concerted effort of... ver más

31/07/2025

SVA

6M€

Presupuesto del proyecto: 6M€

Líder del proyecto

STATENS VETERINAERMEDICINSKA ANSTALT No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 10 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2020-08-11

IMI2-2020-21-01: Development of therapeutics and dia... Specific Challenge:The current coronavirus (COVID-19) outbreak has been declared by WHO as a Public...

I+D

Cerrada hace 5 años

0% 59% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

10 Participantes

SVA

1.28M€ | Lider

MEDIZINISCHE UNIVERSITAET WI...

354.40K€ | Participante

APEIRON BIOLOGICS AG

42.00K€ | Participante

Vironova

1.01M€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 59 meses Fecha Inicio: 2020-08-11
Fecha Fin: 2025-07-31

Líder del proyecto

STATENS VETERINAERMEDICINSKA ANSTALT No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 6M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The SARS-CoV-2 pandemic has become an unprecedented burden to public health, our civil societies and the global economy. To provide frontline therapies for COVID-19 and future corona virus outbreaks requires a concerted effort of different disciplines, technologies, high security labs, and rapid translation of scientific findings to highly innovative and hungry SME partners. For the MAD-CoV-2 project we have assembled a multidisciplinary team of world-leading researchers and innovative industry partners to unlock the Achille’s heels of the virus infections in host cells and rapidly translate such knowledge into disruptive new medicines and public health measures. Our team members have been on the ground of the first SARS and Ebola outbreaks, head containment facilities to study highly infectious viruses, are world-leading in engineering human tissues, developed breakthrough technologies that allow us to find host factors for viral infections at unmatched speed and resolution, and discovered ACE2 and made the first in vivo link between ACE2, SARS, and lung injury, leading to rational drug development which is imminent to be tested in European COVID-19 patients. ACE2 is also the key receptor for SARS-CoV-2 Spike protein and has got centre stage for novel therapies and a fundamental understanding of COVID-19. The aims of MAD-CoV-2 are 1. to engineer human tissues to test novel therapies and vaccines; 2. to provide critical evidence on the role of clinical grade ACE2 in viral replication and COVID-19 pathogenesis; 3. to perform high-throughput screens to genetically map, at a single amino acid resolution, essential host factor that are critical for SARS-CoV-2 replication; and 4. to rapidly translate this knowledge into novel therapies to fight the current and, importantly, future corona virus outbreaks. Our data and unique tissue reagents will be made available to the entire community for drug testing and development, supporting all other efforts.

Conecta tu I+D

Entra hoy

Forgot your password?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores